JAMA Surgery Online First http://www.elizeaboutbeauty.com/journals/jamasurgery en-us Thu, 15 Apr 2021 00:00:00 GMT Thu, 15 Apr 2021 11:43:44 GMT Silverchair jamams@jamanetwork.org support@www.elizeaboutbeauty.com US National Trends in Vascular Surgical Practice During the COVID-19 Pandemic http://www.elizeaboutbeauty.com/journals/jamasurgery/fullarticle/2778881 Thu, 15 Apr 2021 00:00:00 GMT Ho V, Eberhard AV, Asch SM, et al. This national cohort study examines changes in the number of vascular surgical procedures completed in the US before and during the COVID-19 pandemic. 10.1001/jamasurg.2021.1708 2778881 Tranexamic Acid and Safety in the Right Patient http://www.elizeaboutbeauty.com/journals/jamasurgery/fullarticle/2778648 Wed, 14 Apr 2021 00:00:00 GMT Holcomb JB, Sauaia A, Cardenas JC. Tranexamic acid (TXA), an antifibrinolytic agent approved for use in menorrhagia for many decades, has experienced a resurgence of interest and use for both prophylaxis and treatment. TXA works by blocking lysine-binding sites in plasminogen, preventing its binding to fibrin, where it would normally be available for activation by tissue plasminogen activator. It attenuates bleeding if administered early when tissue plasminogen activator is prominent but promotes bleeding if given late when urokinase plasminogen activator is dominant, thereby providing a possible explanation for the observed outcomes of TXA administered after 1 hour from injury and increased mortality when used after 3 hours. There is little doubt that when used appropriately in the various patient populations evaluated with randomized clinical trials, TXA is effective. However, reasonable questions about thrombotic complications remain. The systematic review, meta-analysis, and meta-regression by Taeuber et al attempts to address this issue, yet it evaluated widely diverse populations. e210929 10.1001/jamasurg.2021.0929 2778648 Analysis of Price Transparency for Oncologic Surgery in National Cancer Institute–Designated Cancer Centers in 2020 http://www.elizeaboutbeauty.com/journals/jamasurgery/fullarticle/2778647 Wed, 14 Apr 2021 00:00:00 GMT Xiao R, Miller LE, Workman AD, et al. This cross-sectional analysis reviews hospital chargemasters for a range of cancer surgeries to determine hospitalsâ€?legal compliance with disclosure requirements and the specific prices disclosed. 10.1001/jamasurg.2021.0590 2778647 Blunt Splenic Injury and Prophylactic Splenic Artery Embolization http://www.elizeaboutbeauty.com/journals/jamasurgery/fullarticle/2778646 Wed, 14 Apr 2021 00:00:00 GMT Aoki M, Matsumoto S, Funabiki T. To the Editor We read with interest the article by Arvieux et al, who reported no significant difference in the 1-month spleen salvage rate between prophylactic splenic artery embolization (pSAE) compared with surveillance and then embolization only if necessary (SURV) among patients with splenic trauma at a high risk of rupture. While the researchers concluded that both pSAE and SURV are defendable, they identified some key differences in terms of the secondary outcomes. Namely, pSAE was associated with fewer splenic pseudoaneurysms by day 5 of hospitalization (Pâ€?â€?03), fewer secondary embolizations (Pâ€?amp;lt;â€?001), and a shorter length of hospitalization (Pâ€?â€?002). From these findings, it could be easy to consider pSAE as the most desirable approach, even if patients with severe splenic trauma are hemodynamically stable and have no active arterial extravasation. However, we should interpret these findings with great caution. 10.1001/jamasurg.2021.0625 2778646 Blunt Splenic Injury and Prophylactic Splenic Artery Embolization http://www.elizeaboutbeauty.com/journals/jamasurgery/fullarticle/2778645 Wed, 14 Apr 2021 00:00:00 GMT Windle R, Perin G, Balasubramanian SP. To the Editor We write regarding the recent article by Arvieux et al, which was recently presented at CRAMSURG, an online journal club based in the UK (http://www.cramsurg.org). We would like to congratulate the authors for their efforts in performing a multicenter randomized clinical trial in such a complex area. We discussed a number of issues that we would like to raise. 10.1001/jamasurg.2021.0628 2778645 Implant Surface Texture and Breast Cancer Recurrence http://www.elizeaboutbeauty.com/journals/jamasurgery/fullarticle/2778644 Wed, 14 Apr 2021 00:00:00 GMT de Andrade Urban C, Cavalcante F, El-Tamer MB. To the Editor We read with great interest the study “Association of the Implant Surface Texture Used in Reconstruction With Breast Cancer Recurrence.â€?This is a retrospective cohort study from a single institution in South Korea. The authors compared local and regional recurrence-free survival and disease-free survival rates among patients with smooth and textured implant after reconstruction, finding worse disease-free survival in the textured implant group. It was hypothesized that a chronic inflammatory process could explain the results, just as it happens in breast implant–associated anaplastic large cell lymphoma. This observation is novel and provocative, but we have some questions on the methodology and possible biases. 10.1001/jamasurg.2021.0688 2778644 Implant Surface Texture and Breast Cancer Recurrence http://www.elizeaboutbeauty.com/journals/jamasurgery/fullarticle/2778643 Wed, 14 Apr 2021 00:00:00 GMT Bijlard E, Mureau MM. To the Editor With great interest, we read the study by Lee et al, who investigated the association of breast implant surface texture with the oncological safety in postmastectomy breast reconstruction. They found textured implants are associated with lower disease-free survival, which requires careful interpretation and definitely warrants further research. 10.1001/jamasurg.2021.0691 2778643 Implant Surface Texture and Breast Cancer Recurrence http://www.elizeaboutbeauty.com/journals/jamasurgery/fullarticle/2778642 Wed, 14 Apr 2021 00:00:00 GMT Maarse W, Teunis T. To the Editor There have been concerns regarding breast implants for a long time. On one hand, unfounded claims about autoimmune and connective tissue disease led to unnecessary fear and large-scale litigation. On the other hand, an increased risk of anaplastic large cell lymphoma is now recognized. These contrasting results emphasize the need for close and careful scrutiny. 10.1001/jamasurg.2021.0694 2778642 Blunt Splenic Injury and Prophylactic Splenic Artery Embolization—Reply http://www.elizeaboutbeauty.com/journals/jamasurgery/fullarticle/2778641 Wed, 14 Apr 2021 00:00:00 GMT Arvieux C, Ghelfi J, Foote A. In Reply We are happy that our article published in JAMA Surgery, “Effect of Prophylactic Embolization on Patients With Blunt Trauma at High Risk of Splenectomy: A Randomized Clinical Trial,â€?has stimulated discussion on the feasibility and benefits, or not, of prophylactic splenic artery embolization. 10.1001/jamasurg.2021.0640 2778641 Implant Surface Texture and Breast Cancer Recurrence—Reply http://www.elizeaboutbeauty.com/journals/jamasurgery/fullarticle/2778640 Wed, 14 Apr 2021 00:00:00 GMT Lee K, Bang S. In Reply We deeply appreciate valuable comments provided by de Andrade Urban et al, Bijlard and Mureau, and Maarse and Teunis in response to our study. Thankfully, they addressed several critical points that had not been fully considered during preparation of our original study. 10.1001/jamasurg.2021.0701 2778640 Association of Intravenous Tranexamic Acid With Thromboembolic Events and Mortality http://www.elizeaboutbeauty.com/journals/jamasurgery/fullarticle/2778639 Wed, 14 Apr 2021 00:00:00 GMT Taeuber I, Weibel S, Herrmann E, et al. This systematic review and meta-analysis with meta-regression of 216 randomized clinical trials assesses the association between intravenous administration of tranexamic acid and vascular occlusive events in patients undergoing surgery or experiencing bleeding. e210884 10.1001/jamasurg.2021.0884 2778639 Outcomes With Surgery vs Functional Bracing for Patients With Closed, Displaced Humeral Shaft Fractures http://www.elizeaboutbeauty.com/journals/jamasurgery/fullarticle/2778638 Wed, 14 Apr 2021 00:00:00 GMT Rämö L, Paavola M, Sumrein BO, et al. This secondary analysis of the FISH randomized clinical trial compares the 2-year outcomes of patients who required secondary surgery with the outcomes of patients with successful initial operative or nonoperative treatment. 10.1001/jamasurg.2021.0906 2778638 Addressing Challenges Faced by Female Surgical Trainees With Children During Protected Academic Periods http://www.elizeaboutbeauty.com/journals/jamasurgery/fullarticle/2778637 Wed, 14 Apr 2021 00:00:00 GMT Myers SP, Tzeng E, Downs-Canner SM. This Viewpoint discusses intricacies of childbearing and adoption during surgical training and advises changes to help surgical trainees, particularly women, achieve their professional goals without sacrificing their careers. 10.1001/jamasurg.2021.0583 2778637 4887王中王鉄算 盘开奖结果小说